Free Trial

LifeVantage (LFVN) Competitors

$7.61
+0.05 (+0.66%)
(As of 05/31/2024 ET)

LFVN vs. RZLT, FBLG, ACIU, CTNM, ANL, VTYX, VRCA, ORGO, STTK, and SKYE

Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Rezolute (RZLT), FibroBiologics (FBLG), AC Immune (ACIU), Contineum Therapeutics (CTNM), Adlai Nortye (ANL), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Organogenesis (ORGO), Shattuck Labs (STTK), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.

LifeVantage vs.

Rezolute (NASDAQ:RZLT) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

LifeVantage received 165 more outperform votes than Rezolute when rated by MarketBeat users. Likewise, 77.82% of users gave LifeVantage an outperform vote while only 75.68% of users gave Rezolute an outperform vote.

CompanyUnderperformOutperform
RezoluteOutperform Votes
56
75.68%
Underperform Votes
18
24.32%
LifeVantageOutperform Votes
221
77.82%
Underperform Votes
63
22.18%

83.0% of Rezolute shares are held by institutional investors. Comparatively, 35.3% of LifeVantage shares are held by institutional investors. 20.8% of Rezolute shares are held by insiders. Comparatively, 6.8% of LifeVantage shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LifeVantage has a net margin of 1.75% compared to LifeVantage's net margin of 0.00%. Rezolute's return on equity of 27.02% beat LifeVantage's return on equity.

Company Net Margins Return on Equity Return on Assets
RezoluteN/A -60.90% -54.58%
LifeVantage 1.75%27.02%12.42%

Rezolute currently has a consensus price target of $8.80, suggesting a potential upside of 118.36%. Given LifeVantage's higher possible upside, equities research analysts plainly believe Rezolute is more favorable than LifeVantage.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rezolute
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
LifeVantage
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Rezolute has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

In the previous week, Rezolute had 3 more articles in the media than LifeVantage. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.16 beat Rezolute's score of 1.02 indicating that Rezolute is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rezolute
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LifeVantage
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LifeVantage has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RezoluteN/AN/A-$51.79M-$1.14-3.54
LifeVantage$205.45M0.47$2.54M$0.2827.18

Summary

LifeVantage beats Rezolute on 9 of the 16 factors compared between the two stocks.

Get LifeVantage News Delivered to You Automatically

Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LFVN vs. The Competition

MetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$96.66M$6.73B$5.13B$7.96B
Dividend Yield1.82%2.68%2.75%4.01%
P/E Ratio27.1822.62167.1718.57
Price / Sales0.47392.772,418.7891.65
Price / Cash14.6632.8835.3031.51
Price / Book3.616.085.534.59
Net Income$2.54M$138.60M$106.01M$213.90M
7 Day Performance1.06%3.29%1.14%0.87%
1 Month Performance23.14%1.09%1.43%3.60%
1 Year Performance64.36%-1.29%4.07%7.91%

LifeVantage Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RZLT
Rezolute
3.5996 of 5 stars
$3.69
+3.7%
$8.80
+138.5%
+104.6%$148.08MN/A-3.2457Positive News
FBLG
FibroBiologics
0 of 5 stars
$11.99
+4.4%
N/AN/A$392.31MN/A0.0010Positive News
ACIU
AC Immune
2.2606 of 5 stars
$3.87
+9.3%
$16.00
+313.4%
+102.2%$382.74M$14.80M-5.61133Analyst Forecast
Short Interest ↑
Gap Up
CTNM
Contineum Therapeutics
0 of 5 stars
$14.70
-6.7%
$28.00
+90.5%
N/A$378.13M$50M0.0031Positive News
ANL
Adlai Nortye
1.555 of 5 stars
$10.09
-3.9%
$30.00
+197.2%
N/A$372.42MN/A0.00127Gap Down
High Trading Volume
VTYX
Ventyx Biosciences
1.8582 of 5 stars
$5.13
+17.4%
$21.75
+324.0%
-85.9%$361.67MN/A-1.5879Positive News
VRCA
Verrica Pharmaceuticals
3.6108 of 5 stars
$8.42
-1.6%
$13.50
+60.3%
+49.3%$357.18M$5.12M-4.81100
ORGO
Organogenesis
3.6866 of 5 stars
$2.67
+1.5%
$4.83
+81.0%
-25.3%$353.96M$433.14M66.77862Short Interest ↑
Gap Up
STTK
Shattuck Labs
2.9961 of 5 stars
$7.33
-2.1%
$20.00
+172.9%
+157.1%$348.54M$1.66M-3.8075Positive News
SKYE
Skye Bioscience
0.8942 of 5 stars
$12.30
+2.0%
$22.00
+78.9%
+85,267.6%$345.26MN/A0.0011

Related Companies and Tools

This page (NASDAQ:LFVN) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners